Source: Newsmax

An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined with azithromycin were 66% less likely to die.

Science Direct reports that the study also indicates a “larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease.” 

The study involved 539 coronavirus patients who were hospitalized in Milan between Feb 24-May 17. Of those patients, the study noted that 174 died in the hospital. 

Some of the patients were divided into groups. One group of patients received hydroxychloroquine one day after they were admitted to the hospital. Another group received hydroxychloroquine and azithromycin. A third group received neither drug. The percent of death in the 3 groups was 27%, 23% and 51%, respectively, according to the study results. 

Mechanical ventilation was used in 4.3% of the patients who took hydroxychloroquine, 14.2% of patients who took both drugs and 26.1% of the control group of patients, the study reports. 

The study excluded people who were taking other medications that could have biased the effect of hydroxychloroquine.

Researchers write that they “question whether hydroxychloroquine should be further tested.”

They also state that additional studies should look into when it is best to start treatment. 

The use of the drug has been heavily debated. Some studies have shown the drug to be effective in treating the virus while others have halted studies after finding it is ineffective and can be dangerous and lead to cardiovascular issues. The Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine on June 15. 

Related: France 24: Hydroxychloroquine effective in treating COVID-19, according to study of 2,500

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Zelenko study: COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin; A Retrospective Case Series Study

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »